Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking
NICE recommends Lundbeck's alcohol dependence drug

Alcohol dependent patients in England are set to have access to a new pill to help control their drinking problem.

Health guidance body the National Institute for Health and Care Excellence (NICE) issued final draft guidance backing the use of Lundbeck's Selincro (nalmefene) as an addition to counselling to the 600,000 people in England estimated to be dependent on alcohol.

The drug is intended to help reduce consumption of alcohol, rather than lead to complete abstinence, and in clinical trials it has helped patients cut the amount they drink by an average of 61 per cent after six months.

Andrew Langford, chief executive of the British Liver Trust, said that encouraging alcoholics to drink less could have health benefits on blood pressure, cancer and liver disease, as well as wider effects.

“Reducing alcohol consumption can prevent these social and physical damages developing,” said Langford.

Selincro has already been launched in Northern Europe in countries such as Norway, Finland, Poland, Latvia, Lithuania and Estonia and Lundbeck is likely to ramp up marketing in England once final guidance is published next month.

The drug works by affecting an individual's opioid receptors, which help to control the brain's motivational system. By doing so, the reinforcing effects of alcohol are reduced, resulting in a decrease in the urge to drink.

Lundbeck has high hopes for Selincro as it tries to overcome the impact of the loss of patent protection for its top selling treatment antidepressant Cipralex/Lexapro (escitalopram oxalate).

The company's 'Fit for the Future' programme has seen Lundbeck implement Europe-wide restructuring programmes and hundreds of job losses.

The importance of new products like Selincro became even more apparent over the summer following disappointing late-stage trial results for investigational stroke therapy desmoteplase.

Article by
Thomas Meek

2nd October 2014

From: Sales, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...